Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: Effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats

Journal of Neuroendocrinology

Volumn 20, Issue SUPPL. 1, 2008, Pages 116-123

  Pavon F J ^a,b   Serrano, A ^a,b   Perez Valero V ^a,b   Jagerovic, N ^c   Hernandez Folgado L ^c   Bermudez Silva F J ^a,b   Macias M ^a,b   Goya, P ^c   de Fonseca, Fernando Rodriguez ^a,b,d  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^d UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Cannabinoid antagonist; CB1; Feeding; SCD 1; Zucker

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2 ARACHIDONOYLGLYCEROL; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ACYL COENZYME A DESATURASE; ALANINE AMINOTRANSFERASE; ANOREXIGENIC AGENT; ARACHIDONIC ACID DERIVATIVE; ASPARTATE AMINOTRANSFERASE; CANNABINOID 1 RECEPTOR ANTAGONIST; CHOLESTEROL; CREATININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LH 21; N OLEOYLETHANOLAMINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; RIMONABANT; SR 141716 A; TRIACYLGLYCEROL; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; CREATININE BLOOD LEVEL; DRUG ANTAGONISM; DRUG MECHANISM; DRUG PENETRATION; DRUG RECEPTOR BINDING; ENERGY EXPENDITURE; FEEDING BEHAVIOR; FOOD; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HUMAN; LIPOPROTEIN BLOOD LEVEL; METABOLIC DISORDER; NEUROMODULATION; NONHUMAN; OBESITY; PERIPHERAL NERVE; PRIORITY JOURNAL; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ANIMALS; ANOREXIA; ANTI-OBESITY AGENTS; BIOLOGICAL AVAILABILITY; BRAIN; CANNABINOIDS; CENTRAL NERVOUS SYSTEM; DRUG SYNERGISM; EATING; ENERGY METABOLISM; FEEDING BEHAVIOR; OBESITY; OLEIC ACIDS; PIPERIDINES; PYRAZOLES; RATS; RATS, ZUCKER; RECEPTOR, CANNABINOID, CB1; TRIAZOLES;

EID: 42349102388     PISSN: 09538194     EISSN: 13652826     Source Type: Journal    
DOI: 10.1111/j.1365-2826.2008.01693.x     Document Type: Conference Paper

References (33)

1. Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005; 8: 585-589.
2. Gomez R, Navarro M, Ferrer B, Trigo JM, Bilbao A, Del Arco I, Cippitelli A, Nava F, Piomelli D, Rodriguez de Fonseca F. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 2002; 22: 9612-9617.
3. Kirkham TC. Endocannabinoids in the regulation of appetite and body weight. Behav Pharmacol 2005; 16: 297-313.
4. Rodriguez de Fonseca F, Navarro M, Gomez R, Escuredo L, Nava F, Fu J, Murillo-Rodriguez E, Giuffrida A, LoVerme J, Gaetani S, Kathuria S, Gall C, Piomelli D. An anorexic lipid mediator regulated by feeding. Nature 2001; 414: 209-212.
5. Rodriguez de Fonseca F, Del Arco I, Bermudez-Silva FJ, Bilbao A, Cippitelli A, Navarro M. The endocannabinoid system: Physiology and pharmacology. Alcohol Alcohol 2005; 40: 2-14.
6. Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, Rodriguez de Fonseca F, Rosengarth A, Luecke H, Di Giacomo B, Tarzia G, Piomelli D. Oleoylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 2003; 425: 90-93.
7. Fu J, Oveisi F, Gaetani S, Lin E, Piomelli D. Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats. Neuropharmacology 2005; 48: 1147-1153.
8. Guzman M, Lo Verme J, Fu J, Oveisi F, Blázquez C, Piomelli D. Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha). J Biol Chem 2004; 279: 27849-27854.
9. Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, Schubert M, Auer D, Yassouridis A, Thone-Reineke C, Ortmann S, Tomassoni F, Cervino C, Nisoli E, Linthorst AC, Pasquali R, Lutz B, Stalla GK, Pagotto U. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003; 112: 423-431.
10. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Batkai S, Harvey-White J, Mackie K, Offertaler L, Wang L, Kunos G. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005; 115: 1298-1305.
11. Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Janke J, Batkai S, Pacher P, Harvey-White J, Luft FC, Sharma AM, Jordan J. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005; 54: 2838-2843.
12. Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le Fur G, Oury-Donat F, Soubrie P. The cannabinoid CB1 receptor antagonist SR-141716 increases Acrp-30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003; 63: 908-914.
13. Pavon FJ, Bilbao A, Hernandez-Folgado L, Cippitelli A, Jagerovic N, Abellan G, Rodriguez-Franco MA, Serrano A, Macias M, Gomez R, Navarro M, Goya P, Rodriguez de Fonseca F. Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole-LH 21. Neuropharmacology 2006; 51: 358-366.
14. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J, RIO-North America Study Group. Effect of SR141716A, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patientA: RIO-North America: a randomized controlled trial. JAMA 2006; 295: 761-775.
15. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF, RIO-Diabetes Study Group. Efficacy and tolerability of SR141716A in overweight or obese patients with type 2 diabetes: A randomised controlled study. Lancet 2006; 368: 1660-1672.
16. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S, RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker SR141716A on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389-1397.
17. Vickers SP, Webster LJ, Wyatt A, Dourish CT, Kennett GA. Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology (Berl) 2003; 167: 103-111.
18. Bermudez-Silva FJ, Serrano A, Diaz-Molina FJ, Sanchez Vera I, Juan-Pico P, Nadal A, Fuentes E, Rodriguez de Fonseca F. Activation of cannabinoid CB1 receptors induces glucose intolerance in rats. Eur J Pharmacol 2006; 531: 282-284.
19. Juan-Pico P, Fuentes E, Bermudez-Silva FJ, Diaz-Molina FJ, Ripoll C, Rodriguez de Fonseca F, Nadal A. Cannabinoid receptors regulate Ca(2+) signals and insulin secretion in pancreatic beta-cell. Cell Calcium 2006; 39: 155-162.
20. Cervino C, Pasquali R, Pagotto U. Cannabinoid receptor antagonists and the metabolic syndrome: Novel promising therapeutical approaches. Mini Rev Med Chem 2007; 7: 21-30.
21. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Neliat G, Caput D, Ferrara P, Soubrie PH, Breliere JC, Le Fur G. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994; 350: 240-244.
22. Mato S, Pazos A, Valdizan EM. Cannabinoid receptor antagonism and inverse agonism in response to SR141716A on cAMP production in human and rat brain. Eur J Pharmacol 2002; 443: 43-46.
23. Pertwee RG. Inverse agonism and neutral antagonism at cannabinoid CB(1) receptors. Life Sci 2005; 76: 1307-1324.
24. Jagerovic N, Hernandez-Folgado L, Alkorta I, Goya P, Navarro M, Serrano A, Rodriguez de Fonseca F, Dannert MT, Alsasua A, Suardiaz M, Pascual D, Martin MI. Discovery of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1h-1,2,4-triazole, a novel in vivo cannabinoid antagonist containing a 1,2,4-triazole motif. J Med Chem 2004; 47: 2939-2942.
25. Serrano A, Del Arco I, Pavon FJ, Macias M, Perez-Valero V, Rodriguez de Fonseca F. The cannabinoid CB1 receptor antagonist SR141716A (SR141716A) enhances the metabolic benefits of long term treatment with oleoylethanolamide in Zucker rats. Neuropharmacology 2007; DOI 10.1016/ j.neuropharm.2007.03.007.
26. Phillips MS, Liu Q, Hammond HA, Dugan V, Hey PJ, Caskey CJ, Hess JF. Leptin receptor missense mutation in the fatty Zucker rat. Nat Genet 1996; 13: 18-19.
27. Bermúdez-Silva FJ, Suárez J, Baixeras E, Cobo N, Bautista D, Cuesta-Muñoz AL, Fuentes E, Juan-Pico P, Castro MJ, Milman G, Mechoulam R, Nadal A, Rodríguez de Fonseca F. Presence of functional cannabinoid receptors in human endocrine pancreas. Diabetologia 2008; 51: 51476-51487.
28. Serrano A, Pavon J, del Arco I, Rojo G, Soriguer F, Rodriguez de Fonseca F. Oleoylethanolamide regulates level of fatty acids in rats via down-regulation of liver desaturases mRNA expression. Obesity and Metabolism 2006; 2: 155-164.
29. Cohen P, Miyazaki M, Socci ND, Hagge-Greenberg A, Liedtke W, Soukas AA, Sharma R, Hudgins LC, Ntambi JM, Friedman JM. Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss. Science 2002; 297: 240-243.
30. Levy JR, Clore JN, Stevens W. Dietary n-3 polyunsaturated fatty acids decrease hepatic triglycerides in Fischer 344 rats. Hepatology 2004; 39: 608-616.
31. Miyazaki M, Kim YC, Gray-Keller MP, Attie AD, Ntambi JM. The biosynthesis of hepatic cholesterol esters and triglycerides is impaired in mice with a disruption of the gene for stearoyl-CoA desaturase 1. J Biol Chem 2000; 275: 30132-30138.
32. Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, Mackie K. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci U S A. 2008 Feb 8; [Epub ahead of print].
33. Rodriguez de Fonseca F, Navarro M, Alvarez E, Roncero I, Chowen JA, Maestre O, Gomez R, Munoz RM, Eng J, Blazquez E. Peripheral versus central effects of glucagon-like peptide-1 receptor agonista on satiety and body weight loss in Zucker obese rats. Metabolism 2000; 49: 709-717.